论文部分内容阅读
目的:探讨我院2012~2014年口服核苷(酸)类药物抗乙肝病毒的使用情况,分析其特点及用药发展趋势,为临床合理用药提供可靠的参考。方法:统计我院2012~2014年核苷(酸)类药物的销售金额、构成比、DDDs及排名。结果:2012~2014年我院口服核苷(酸)类药物销售金额逐年上升,其中恩替卡韦、替比夫定的销售金额及用药频度逐年上涨,恩替卡韦、阿德福韦酯构成比远超其他药物。结论:目前我院核苷(酸)类抗病毒药物在临床上使用量逐年增加,其中,恩替卡韦在临床应用中更有优势。
Objective: To investigate the use of oral nucleoside (acid) drugs against hepatitis B virus in our hospital from 2012 to 2014, analyze its characteristics and development trend of drug use, and provide a reliable reference for clinical rational drug use. Methods: Statistics in our hospital from 2012 to 2014 nucleotide (acid) drugs sales amount, composition, DDDs and rankings. Results: From 2012 to 2014, the sales volume of oral nucleoside (acid) drugs in our hospital increased year by year. The sales amount of entecavir and telbivudine increased year by year, and the proportion of entecavir and adefovir dipivoxil was much higher than that of other drugs drug. CONCLUSION: At present, the usage of nucleoside (acid) antiviral drugs in our hospital has been increasing year by year. Among them, entecavir has more advantages in clinical application.